News
Public · Published
Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile
Harmony Biosciences reported third-quarter 2026 WAKIX net revenue of $269 million and 400 net patient additions, and reiterated full-year revenue guidance of $1.0 billion to $1.04 billion. It also reported favorable safety, tolerability, and drug-level data from a multiple-dose study of BP-205.
Published:
Updated:
What happened
Harmony Biosciences reported third-quarter 2026 WAKIX net revenue of $269 million and 400 net patient additions, and reiterated full-year revenue guidance of $1.0 billion to $1.04 billion. It also reported favorable safety, tolerability, and drug-level data from a multiple-dose study of BP-205.
Confirmed
Global impact / market context
WAKIX sales and patient additions indicate the current product is generating substantial revenue, while the reiterated forecast gives investors a stated full-year target. BP-205’s early study results may support future development, but it remains investigational and does not yet add commercial revenue.
Analyst inference
The supplied update combines sales from an existing medicine with preliminary results for a potential new drug. WAKIX revenue depends on continued demand, while BP-205’s value depends on later studies and regulatory progress; the article provides no evidence of a market-price reaction.
Analyst inference
What to watch
- Track subsequent WAKIX revenue and patient additions against the reiterated $1.0 billion to $1.04 billion full-year guidance; weaker demand could make that target harder to meet. Analyst inference
- The company says Phase 1b results for BP-205 remain on track for Q1 2027, with Phase 2 studies in several central nervous system conditions expected by mid-2027. Confirmed
- Watch whether later BP-205 studies reproduce the reported safety and drug-level profile; disappointing results could delay development and reduce the prospect of future product revenue. Analyst inference